Advances in Antibody-Based Therapeutics for Cerebral Ischemia

Jui Ming Sun, Ting Lin Yen, Jing Shiun Jan, Pharaoh Fellow Mwale, Ruei Dun Teng, Rajeev Taliyan, Cheng Ta Hsieh, Chih Hao Yang

Research output: Contribution to journalReview articlepeer-review

1 Citation (Scopus)

Abstract

Cerebral ischemia is an acute disorder characterized by an abrupt reduction in blood flow that results in immediate deprivation of both glucose and oxygen. The main types of cerebral ischemia are ischemic and hemorrhagic stroke. When a stroke occurs, several signaling pathways are activated, comprising necrosis, apoptosis, and autophagy as well as glial activation and white matter injury, which leads to neuronal cell death. Current treatments for strokes include challenging mechanical thrombectomy or tissue plasminogen activator, which increase the danger of cerebral bleeding, brain edema, and cerebral damage, limiting their usage in clinical settings. Monoclonal antibody therapy has proven to be effective and safe in the treatment of a variety of neurological disorders. In contrast, the evidence for stroke therapy is minimal. Recently, Clone MTS510 antibody targeting toll-like receptor-4 (TLR4) protein, ASC06-IgG1 antibody targeting acid sensing ion channel-1a (ASIC1a) protein, Anti-GluN1 antibodies targeting N-methyl-D-aspartate (NMDA) receptor associated calcium influx, GSK249320 antibody targeting myelin-associated glycoprotein (MAG), anti-High Mobility Group Box-1 antibody targeting high mobility group box-1 (HMGB1) are currently under clinical trials for cerebral ischemia treatment. In this article, we review the current antibody-based pharmaceuticals for neurological diseases, the use of antibody drugs in stroke, strategies to improve the efficacy of antibody therapeutics in cerebral ischemia, and the recent advancement of antibody drugs in clinical practice. Overall, we highlight the need of enhancing blood–brain barrier (BBB) penetration for the improvement of antibody-based therapeutics in the brain, which could greatly enhance the antibody medications for cerebral ischemia in clinical practice.

Original languageEnglish
Article number145
JournalPharmaceutics
Volume15
Issue number1
DOIs
Publication statusPublished - Jan 2023

Keywords

  • antibody
  • blood brain barrier
  • cerebral ischemia
  • hemorrhagic
  • ischemic

ASJC Scopus subject areas

  • Pharmaceutical Science

Fingerprint

Dive into the research topics of 'Advances in Antibody-Based Therapeutics for Cerebral Ischemia'. Together they form a unique fingerprint.

Cite this